search
Back to results

Safety and Efficacy of Express LD to Treat Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries (MELODIE)

Primary Purpose

Arterial Occlusive Disease, Intermittent Claudication, Atherosclerotic Disease

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
stent implantation
Sponsored by
Boston Scientific Corporation
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Arterial Occlusive Disease focused on measuring iliac arteries, implantation, treatment of atherosclerotic disease, stenosed, occlusive

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: chronic symptomatic atherosclerotic disease in the iliac arteries (Fontaine Class IIa, IIb, and III) atherosclerotic de novo or restenotic lesions in the common and/or external iliac artery. baseline diameter stenosis of > or = 50% reference vessel diameter > or = 5mm and < or = 10mm at least one sufficient ipsilateral infrapopliteal run-off length of diseased segment(s) < or = 10cm and can be treated with maximally two overlapping Express Vascular LD Stents. multiple target lesions of the iliac arteries in the same patient can be included provided if each target lesion is compliant with the antiographic inclusion criteria and non-compliant with any of the antiographic exclusion criteria, target lesions are not located in the same target axis, and all target lesions can be treated during the same procedure. Exclusion Criteria: chronic symptomatic atherosclerotic disease classified as fontaine Class I or IV acute leg ischemia pregnants patients patients with uncorrected bleeding disorders (platelets < 150 000/mm3 or > 450 000 mm3, or patient who cannot receive anticoagulation or antiplatelet aggregation therapy patient with known allergy to stainless steel known anaphylactoid or other non-anaphylactic reactions to contrast agents that cannot be adequately premedicated prior to the index procedure life-expectancy of less than 24 months due to other medical co-morbid condition that could limit patient's ability to participate in the study, the patient's compliance with the follow-up requirements or impact the scientific integrity of the study patient currently participating in another study that has not yet completed the primary endpoint or that clinically interferes with the endpoint of this study patients who have already participated in this study patients with prior or planned bypass surgery of the target vessel patient with prior stent placement in the target vessel patient with any previous coronary intervention within the last 30 days before enrollment into this study or patients with planned coronary intervention within 30 days after enrollment into this study. patients in whom the origin of the profunda femoris and superficial femoral artery is occluded in the limb supplied by the iliac artery to be treated without planned surgical repair patients with heavily calcified and excessive tortuous lesions at the target site as determined by angiography patients with target lesion which is within or adjacent to the proximal or distal segment of an aneurysm patients with persistent, acute intraluminal thrombus of the proposed target lesion site post-thrombolytic therapy patients with perforated vessels as evidenced by extravasation of contrast media patients with multiple lesions in the same target vessels.

Sites / Locations

  • Limburgs Vaatcentrum Ziekenhuis Oost-Limburg
  • Sint Trudo Hospital
  • CHUM- Notre Dame Hospital
  • General Teaching Hospital Prague
  • Institute for Clinical and Experimental Medicine (IKEM)
  • Sint Antonius Hospital
  • University Hospital of Krakow
  • University School of Medicine
  • Center of Diagnostic Imaging and Vascular Disease Treatment
  • Samodzielny Publiczny Centraln Szpital

Outcomes

Primary Outcome Measures

Angiographic mean percent loss of luminal diameter at 6 months post-procedure defined as ((post-procedure MLD - Follow-up MLD)/Post-procedure MLD) X 100

Secondary Outcome Measures

hemodynamic success at hospital discharge, 30 days and 6, 12 and 24 months post-procedure, angiographic binary restenosis at 6 mont

Full Information

First Posted
July 12, 2006
Last Updated
September 25, 2008
Sponsor
Boston Scientific Corporation
Collaborators
KIKA
search

1. Study Identification

Unique Protocol Identification Number
NCT00352222
Brief Title
Safety and Efficacy of Express LD to Treat Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries
Acronym
MELODIE
Official Title
A Prospective, Multicenter, Single Arm Study to Obtain Additional Data on the Safety and Efficacy of the Express Vascular LD Implantation in the Treatment of Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries
Study Type
Interventional

2. Study Status

Record Verification Date
September 2008
Overall Recruitment Status
Completed
Study Start Date
January 2004 (undefined)
Primary Completion Date
July 2005 (Actual)
Study Completion Date
February 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Boston Scientific Corporation
Collaborators
KIKA

4. Oversight

5. Study Description

Brief Summary
To obtain additional data on safety and efficacy of the Express stent implantation in the treatment of stenosed or occlusive atherosclerotic disease (de novo or restenotic lesions) in the iliac arteries (common or external).
Detailed Description
This study was conducted to provide additional data on the safety and efficacy of the Express™ Vascular LD stent, particularly with regard to the long-term patency in iliac arteries. The study would provide data on angiographic endpoints and clinical outcomes at 30 days, 6 months, and at 12 and 24 months post implantation in atherosclerotic lesions in iliac arteries. The data obtained in this study with the use of the Express™ Vascular LD stent was compared with historical data obtained from the use of the Palmaz balloon-expandable stent. The Palmaz balloon expandable stent has been chosen as the control device because it is currently the only FDA-approved balloon-expandable stent for use in the percutaneous treatment of atherosclerotic disease in iliac arteries. The Palmaz balloon-expandable stent is no longer commercialized in Europe. Therefore a randomized study with the Palmaz balloon-expandable stent was not feasible. In addition, there are no ongoing or published randomized trials describing performance of a newer version of the Palmaz stent in iliac atherosclerotic lesions. In order to adequately compare the efficacy data of the ExpressTM Vascular LD stent with the efficacy data of the Palmaz balloon-expandable stent, the same efficacy parameter as in the publication on the Palmaz balloon-expandable stent was measured in this study: % mean loss of the luminal diameter at 6 months post-procedure. The findings of the longer-term Follow-Up assessments at 12 and 24 months will be presented as the results from these assessments become available.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Arterial Occlusive Disease, Intermittent Claudication, Atherosclerotic Disease, Thrombosis
Keywords
iliac arteries, implantation, treatment of atherosclerotic disease, stenosed, occlusive

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
150 (false)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
stent implantation
Primary Outcome Measure Information:
Title
Angiographic mean percent loss of luminal diameter at 6 months post-procedure defined as ((post-procedure MLD - Follow-up MLD)/Post-procedure MLD) X 100
Secondary Outcome Measure Information:
Title
hemodynamic success at hospital discharge, 30 days and 6, 12 and 24 months post-procedure, angiographic binary restenosis at 6 mont

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: chronic symptomatic atherosclerotic disease in the iliac arteries (Fontaine Class IIa, IIb, and III) atherosclerotic de novo or restenotic lesions in the common and/or external iliac artery. baseline diameter stenosis of > or = 50% reference vessel diameter > or = 5mm and < or = 10mm at least one sufficient ipsilateral infrapopliteal run-off length of diseased segment(s) < or = 10cm and can be treated with maximally two overlapping Express Vascular LD Stents. multiple target lesions of the iliac arteries in the same patient can be included provided if each target lesion is compliant with the antiographic inclusion criteria and non-compliant with any of the antiographic exclusion criteria, target lesions are not located in the same target axis, and all target lesions can be treated during the same procedure. Exclusion Criteria: chronic symptomatic atherosclerotic disease classified as fontaine Class I or IV acute leg ischemia pregnants patients patients with uncorrected bleeding disorders (platelets < 150 000/mm3 or > 450 000 mm3, or patient who cannot receive anticoagulation or antiplatelet aggregation therapy patient with known allergy to stainless steel known anaphylactoid or other non-anaphylactic reactions to contrast agents that cannot be adequately premedicated prior to the index procedure life-expectancy of less than 24 months due to other medical co-morbid condition that could limit patient's ability to participate in the study, the patient's compliance with the follow-up requirements or impact the scientific integrity of the study patient currently participating in another study that has not yet completed the primary endpoint or that clinically interferes with the endpoint of this study patients who have already participated in this study patients with prior or planned bypass surgery of the target vessel patient with prior stent placement in the target vessel patient with any previous coronary intervention within the last 30 days before enrollment into this study or patients with planned coronary intervention within 30 days after enrollment into this study. patients in whom the origin of the profunda femoris and superficial femoral artery is occluded in the limb supplied by the iliac artery to be treated without planned surgical repair patients with heavily calcified and excessive tortuous lesions at the target site as determined by angiography patients with target lesion which is within or adjacent to the proximal or distal segment of an aneurysm patients with persistent, acute intraluminal thrombus of the proposed target lesion site post-thrombolytic therapy patients with perforated vessels as evidenced by extravasation of contrast media patients with multiple lesions in the same target vessels.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Luc Stockx, MD
Organizational Affiliation
Limburgs Vaatcentrum Ziekenhuis Oost-Limburg, Belgium
Official's Role
Principal Investigator
Facility Information:
Facility Name
Limburgs Vaatcentrum Ziekenhuis Oost-Limburg
City
Genk
ZIP/Postal Code
3600
Country
Belgium
Facility Name
Sint Trudo Hospital
City
Sint Truiden
ZIP/Postal Code
3800
Country
Belgium
Facility Name
CHUM- Notre Dame Hospital
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H2L 4M1
Country
Canada
Facility Name
General Teaching Hospital Prague
City
Praha
ZIP/Postal Code
12808
Country
Czech Republic
Facility Name
Institute for Clinical and Experimental Medicine (IKEM)
City
Praha
ZIP/Postal Code
14021
Country
Czech Republic
Facility Name
Sint Antonius Hospital
City
Nieuwegein
State/Province
CM
ZIP/Postal Code
3435
Country
Netherlands
Facility Name
University Hospital of Krakow
City
Krakow
ZIP/Postal Code
31-066
Country
Poland
Facility Name
University School of Medicine
City
Lublin
ZIP/Postal Code
20-954
Country
Poland
Facility Name
Center of Diagnostic Imaging and Vascular Disease Treatment
City
Szczecin
ZIP/Postal Code
71-232
Country
Poland
Facility Name
Samodzielny Publiczny Centraln Szpital
City
Warszawa
ZIP/Postal Code
02-097
Country
Poland

12. IPD Sharing Statement

Citations:
PubMed Identifier
20939723
Citation
Stockx L, Poncyljusz W, Krzanowski M, Schroe H, Allocco DJ, Dawkins KD; MELODIE Investigators. Express LD vascular stent in the treatment of iliac artery lesions: 24-month results from the MELODIE trial. J Endovasc Ther. 2010 Oct;17(5):633-41. doi: 10.1583/09-2917MR.1.
Results Reference
derived

Learn more about this trial

Safety and Efficacy of Express LD to Treat Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries

We'll reach out to this number within 24 hrs